Angiotensin receptor blocker selection for stroke risk reduction
For secondary stroke prevention in patients with prior stroke or transient ischemic attack (TIA), angiotensin receptor blocker (ARB) therapy is recommended as a drug-class option for blood pressure reduction. [1] Current guidance does not provide a comparative “ranking” among individual ARBs for recurrent stroke prevention. [1]
Medication selection algorithm
The recommended ARB role is within antihypertensive therapy selection for secondary stroke prevention. [1]
Individual ARB selection should be individualized based on comorbidities and agent pharmacological class. [1]
Common ARB options used for hypertension include the following (examples): [2]-[5]
- Losartan (for example, losartan potassium). [2]
- Valsartan (for example, valsartan tablets). [3]
- Candesartan (for example, candesartan cilexetil). [4]
- Telmisartan (for example, telmisartan tablets). [5]
Target blood pressure goal
For adults with a prior stroke or TIA and hypertension, a blood pressure goal of less than 130/80 mm Hg may be reasonable. [1]
Initiation thresholds and timing after stroke
For adults with previously treated hypertension who experience stroke or TIA, antihypertensive therapy should be restarted after the first few days of the index event. [1] For adults not previously treated for hypertension who experience stroke or TIA and have an established blood pressure of 140/90 mm Hg or higher, antihypertensive treatment should be prescribed a few days after the index event. [1]
Core ARB recommendation strength for stroke prevention
For adults who experience stroke or TIA, treatment with a thiazide diuretic, angiotensin-converting enzyme (ACE) inhibitor, or ARB, or combination treatment consisting of a thiazide diuretic plus ACE inhibitor is useful to reduce recurrent stroke risk. (Class I, Level A for ARB-containing drug-class recommendation). [1]
Dosing recommendations (adult hypertension; titration by response)
These dosing regimens are drawn from U.S. prescribing information for hypertension dosing and titration. [2]-[5]
Losartan
- Usual starting dose: 50 mg once daily. [2]
- Maximum dose for hypertension: 100 mg once daily. [2]
- Lower starting dose for possible intravascular depletion: 25 mg once daily. [2]
Valsartan
- Usual starting dose (monotherapy, not volume-depleted): 80 mg once daily or 160 mg once daily. [3]
- Dose range: 80 mg to 320 mg once daily. [3]
Candesartan
- Usual adult target regimen range: 8 mg to 32 mg total daily dose once daily. [4]
- Monotherapy starting approach reflected in labeling: 16 mg tablet once daily with an 8 mg to 32 mg total daily dose range. [4]
- Dosing schedule: once daily or twice daily administration with total daily dose in the 8 mg to 32 mg range. [4]
Telmisartan
- Usual starting dose: 40 mg once daily. [5]
- Dose range for hypertension effect: 20 mg to 80 mg once daily. [5]
Common pitfalls to avoid
Initiation timing errors after acute stroke may worsen outcomes; antihypertensive therapy is recommended to be restarted or initiated after the first few days after the index event for secondary prevention. [1]
Drug-class ranking conclusion for stroke prevention
No head-to-head guideline ranking exists for individual ARBs for recurrent stroke prevention; any guideline-supported ARB-based blood pressure lowering regimen is consistent with recommended secondary prevention. [1] Dosing should follow the labeled adult hypertension regimens for the selected ARB and be titrated to achieve the secondary prevention blood pressure goal. [1]-[5]